Anzeige
Mehr »
Login
Mittwoch, 19.02.2025 Börsentäglich über 12.000 News von 688 internationalen Medien
Dominiert dieses Medizin-KI-Unternehmen bald den Gesundheitsmarkt?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3E4MT | ISIN: US78397T2024 | Ticker-Symbol:
NASDAQ
18.02.25
20:21 Uhr
1,930 US-Dollar
-0,010
-0,52 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
SAB BIOTHERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
SAB BIOTHERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur SAB BIOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
05.02.SAB Biotherapeutics, Inc. - 8-K, Current Report-
28.01.Why Is SAB BIO Stock Trading Lower On Tuesday?6
28.01.Pre-market Movers: IMAC Holdings, Planet Image International, SAB Biotherapeutics, MicroCloud Hologram, Avalon Holdings428BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.30 A.M. ET).In the Green IMAC Holdings, Inc. (BACK) is up over 91% at $1.59. Planet...
► Artikel lesen
28.01.SAB Biotherapeutics, Inc.: SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142333SAB-142 was generally well-tolerated among healthy volunteers; data from Phase 1 trial confirms SAB-142 does not cause serum sickness or anti-drug antibodies at target dose Study results support...
► Artikel lesen
28.01.SAB Biotherapeutics, Inc. - 8-K, Current Report-
23.01.SAB Biotherapeutics, Inc.: SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy4
06.01.Here's Why SAB Biotherapeutics, Inc. (NASDAQ:SABS) Is Among the Best Diabetes Stocks to Buy Under $101
07.11.24SAB Biotherapeutics GAAP EPS of -$1.121
SAB BIOTHERAPEUTICS Aktie jetzt für 0€ handeln
06.11.24SAB Biotherapeutics, Inc.: SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update131Company announced completed Phase 1 enrollment for SAB-142 with no observation of serum sickness. The company remains on track for a topline Phase 1 data readout by the end of the year. MIAMI, Nov....
► Artikel lesen
06.11.24SAB Biotherapeutics, Inc. - 10-Q, Quarterly Report-
13.09.24SAB Biotherapeutics, Inc.: SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference1
12.09.24Oppenheimer keeps Outperform rating on SAB Biotherapeutics shares1
09.09.24SAB Biotherapeutics, Inc. - 8-K, Current Report1
04.09.24SAB Biotherapeutics, Inc.: SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting1
08.08.24SAB Biotherapeutics, Inc.: SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates196FDA provided clearance to SAB's IND Appointed Lucy To as Chief Financial Officer Announced founding of a new Clinical Advisory Board MIAMI, Aug. 08, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS)...
► Artikel lesen
05.08.24SAB Biotherapeutics, Inc.: SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes515MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS) (the "Company" or "SAB"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing...
► Artikel lesen
31.07.24SAB Biotherapeutics, Inc.: SAB BIO Appoints Lucy To as Chief Financial Officer146MIAMI, July 31, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is...
► Artikel lesen
20.06.24SAB Biotherapeutics, Inc.: SAb Biotherapeutics Rebrands as SAB BIO169New name, logo and website updates, stock symbol will remain SABS With new brand identity, SAB BIO continues drive towards serious unmet needs in type 1 diabetes MIAMI, June 20, 2024 (GLOBE NEWSWIRE)...
► Artikel lesen
30.05.24SAB Biotherapeutics, Inc.: SAB Biotherapeutics Announces Departure of Chief Financial Officer226MIAMI, May 30, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the "Company" or "SAB"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human...
► Artikel lesen
21.05.24SAB Biotherapeutics, Inc.: FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics267MIAMI, May 21, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the "Company" or "SAB"), today announced that the U.S. Food and Drug Administration (FDA) has provided clearance for the...
► Artikel lesen
Seite:  Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen